Biodexa Pharmaceuticals PLC has formally requested the Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form F-1. The company has proposed the new effective date to be 5:00 p.m. Eastern Time on March 27, 2024. This request was made under Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended. Biodexa Pharmaceuticals' CEO and CFO, Stephen Stamp, signed the request, which was communicated via a letter to the SEC, specifically addressed to Christopher Edwards. The company's counsel, Jason S. McCaffrey of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., is the point of contact for any comments or questions the SEC might have regarding the Registration Statement.

Biodexa Pharmaceuticals PLC has formally requested the Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form F-1. The company has proposed the new effective date to be 5:00 p.m. Eastern Time on March 27, 2024. This request was made under Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended. Biodexa Pharmaceuticals' CEO and CFO, Stephen Stamp, signed the request, which was communicated via a letter to the SEC, specifically addressed to Christopher Edwards. The company's counsel, Jason S. McCaffrey of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., is the point of contact for any comments or questions the SEC might have regarding the Registration Statement.